Harrow (NASDAQ:HROW) Trading Down 5.1% – Should You Sell?

Harrow, Inc. (NASDAQ:HROW) traded down 5.1% during trading on Wednesday . The stock traded as low as $30.25 and last traded at $30.15. 33,546 shares traded hands during trading, a decline of 90% from the average session volume of 322,835 shares. The stock had previously closed at $31.75.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HROW shares. B. Riley lowered their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright started coverage on shares of Harrow in a research note on Thursday, February 6th. They set a “buy” rating and a $57.00 price objective for the company.

Harrow Stock Performance

The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market cap of $1.07 billion, a P/E ratio of -32.10 and a beta of 0.69. The business’s 50-day simple moving average is $34.58 and its 200 day simple moving average is $39.89.

Institutional Trading of Harrow

Institutional investors have recently made changes to their positions in the business. Quest Partners LLC bought a new stake in Harrow in the 3rd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Harrow by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. Hills Bank & Trust Co acquired a new position in Harrow during the third quarter valued at $107,000. AlphaQuest LLC boosted its position in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after purchasing an additional 2,889 shares in the last quarter. Finally, Huntington National Bank purchased a new position in Harrow in the 3rd quarter valued at about $164,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.